ctDNA and immune biomarker testing for molecular residual disease surveillance and immune stratification in cancer
Ning Cui, Hongying Hao, Xiaofeng Hu, Yaxuan Li · 2026
Read ctDNA and immune biomarker testing for molecular residual disease surveillance and immune stratification in cancer by Ning Cui, Hongying Hao, Xiaofeng Hu, Yaxuan Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13598389.txt.
Description
Cui and co-authors wrote a mini review, published in 2026, on hunting the last traces of cancer after treatment. Some cancer cells survive below the reach of scans and later seed a relapse. Blood tests can now find fragments of tumor DNA floating in the bloodstream. Those fragments give a peek at the hidden residue without a biopsy. But reading them is tricky: the amount shed varies with tumor size, site, and treatment timing.
The review pairs the DNA tests with immune markers. The immune data show whether the body is spotting and holding the residue, or letting it slip away. Together the two tests can sort patients by risk and by likely response to immune therapy. The authors survey both tumor-guided and tumor-blind DNA methods. Their synthesis aims at surveillance plans that catch relapse while it is still small.
Catalog record
| CREATOR | Ning Cui, Hongying Hao, Xiaofeng Hu, Yaxuan Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |